David A Ruddy

David A Ruddy

UNVERIFIED PROFILE

Are you David A Ruddy?   Register this Author

Register author
David A Ruddy

David A Ruddy

Publications by authors named "David A Ruddy"

Are you David A Ruddy?   Register this Author

21Publications

1429Reads

38Profile Views

Distinct Transcriptional Programming Drive Response to MAPK Inhibition in -Mutant Melanoma Patient-Derived Xenografts.

Mol Cancer Ther 2019 12 16;18(12):2421-2432. Epub 2019 Sep 16.

Oncology Drug Discovery, Novartis Institutes for BioMedical Research (NIBR), Cambridge, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-19-0028DOI Listing
December 2019

Hyperactivation of MAPK Signaling Is Deleterious to RAS/RAF-mutant Melanoma.

Mol Cancer Res 2019 01 10;17(1):199-211. Epub 2018 Sep 10.

Oncology, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1541-7786.MCR-18-0327DOI Listing
January 2019

Degron mediated BRM/SMARCA2 depletion uncovers novel combination partners for treatment of BRG1/SMARCA4-mutant cancers.

Biochem Biophys Res Commun 2019 01 4;508(1):109-116. Epub 2018 Dec 4.

Oncology, Novartis Institutes for Biomedical Research, Cambridge, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0006291X183191
Publisher Site
http://dx.doi.org/10.1016/j.bbrc.2018.09.009DOI Listing
January 2019

BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.

Mol Cancer Res 2017 10 27;15(10):1431-1444. Epub 2017 Jun 27.

Oncology Disease Area, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1541-7786.MCR-17-0211DOI Listing
October 2017

Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening.

Cell 2017 Jul;170(3):577-592.e10

Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel 4002, Switzerland; Cambridge, MA 02139, USA; and Emeryville, CA 94608, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2017.07.005DOI Listing
July 2017

An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).

Cancer Discov 2013 Sep 10;3(9):1030-43. Epub 2013 Jul 10.

1Oncology Disease Area, 2Department of Oncology Translational Medicine, Novartis Institutes for BioMedical Research, Cambridge; and 3Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://cancerdiscovery.aacrjournals.org/cgi/doi/10.1158/2159
Publisher Site
http://dx.doi.org/10.1158/2159-8290.CD-13-0142DOI Listing
September 2013